JPRN-UMIN000001730已完成1 期
Pilot study of gefitinib and irinotecan in young patients With Relapsed or Refractory Cancer - Ir2 for Relapsed Pediatric and AYA cancer pilot trial
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital pediatric division/musculoskeltal oncology division/ neurology division0 个研究点目标入组 6 人开始时间: 2009年2月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 40years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.>4 weeks since prior CYP3A4 inducer uptake 2.>1 week since prior CYP3A4 inhibitor uptake 3.Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment 4.Active infection requiring systemic medication 5.abnormality in electrocardiogram tested within 28 days, requiring intervention 6.respiratory or heart disorder requiring oxygen supply, except from malignant pleural effusion 7.Women during pregnancy or breast-feeding 8.Psychosis 9.Systemic steroids or immunosuppressants medication except for continuous steroid use for increased intracranial pressure and/or brain edema
研究者
相似试验
撤回
2 期
A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitorsadvanced stage non-small cell lung cancermetastatic non-small cell lung cancer1003866610029107NL-OMON37908Vrije Universiteit Medisch Centrum48
进行中（未招募）
不适用
Treatment with gefitinib and fulvestrant in patients with non-small cell lungcancerPatients with pathologically documented NSCLC with an EGFR mutation, who failed previous treatment with reversible EGFR TKI’s (gefitinib or erlotinib).EUCTR2012-000345-12-NLVU Medical Center
招募中
1 期
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
已完成
3 期
Phase III study of gefitinib versus erlotinib in patients with previously treated lung adeno carcinomaPreviously treated lung adeno carcinomaJPRN-UMIN000002014West Japan Oncology Group560
已完成
不适用
Gefitinib and fulvestrant in patients with advanced, EGFR mutated NSCLC pretreated with EGFR TKI's.NL-OMON28300VU University Medical Center48